01:21 , Jan 12, 2018 |  BC Innovations  |  Translation in Brief

In the twenties

A Cancer Cell study from University of Southampton and Celldex Therapeutics Inc. (NASDAQ:CLDX) researchers suggests combining CD27 agonists with tumor-targeting mAbs could help myeloid cells attack a broad array of cancers. The partners are testing...
07:00 , May 19, 2014 |  BC Week In Review  |  Company News

Celldex, Bristol-Myers deal

Celldex partnered with Bristol-Myers Squibb in an exclusive deal to evaluate combinations of anti- PD-1 receptor ( PDCD1; PD-1; CD279) antagonist antibodies with anti- CD27 agonist antibodies. Under the deal, Celldex will run a...
01:12 , May 15, 2014 |  BC Extra  |  Top Story

BMS, Celldex to study nivolumab, CDX-1127

Celldex Therapeutics Inc. (NASDAQ:CLDX) jumped $3.34 (27%) to $15.74 on Wednesday after announcing an exclusive deal with Bristol-Myers Squibb Co. (NYSE:BMY) to evaluate combinations of anti- PD-1 receptor ( PDCD1; PD-1; CD279) antagonist antibodies with...